ADP101 multifood oral immunotherapy for food-allergic patients: Harmony phase 1/2 randomized clinical trial
The study did not meet its primary endpoint, but ADP101 demonstrated a favorable safety profile and increased the reactive threshold in DBPCFC in pediatric participants with single or multiple food allergies across multiple endpoints, warranting further clinical investigation.
Authors
- Mei‐Lun Wang (ORCID: https://orcid.org/0000-0003-2735-9833)
- Lisa Tuomi (ORCID: https://orcid.org/0000-0003-2081-3589)
- Dana McClintock
- Amal Assa’ad (ORCID: https://orcid.org/0000-0001-7791-6859)
- S. Gogate
- Ouhong Wang
- Daniel Petroni (ORCID: https://orcid.org/0000-0002-3533-4401)
- Thomas B. Casale (ORCID: https://orcid.org/0000-0002-3149-7377)
- Edwin Kim (ORCID: https://orcid.org/0000-0001-6418-1785)
- A. Campbell Sullivan
- Ashley Dombkowski
- Cheri Piscia‐Nichols
- Olga Levin-Young
- Warner Carr (ORCID: https://orcid.org/0000-0002-6519-5860)
- Amy M. Archer
Institutions
- University of North Carolina at Chapel Hill (US)
- Cincinnati Children's Hospital Medical Center (US)
- University of South Florida (US)
- Center Point (US)
- Allergy, Asthma and Clinical Research Center (US)
- OSE Immunotherapeutics (France) (FR)
- Allergy Asthma Research Institute (US)
- Asthma Association (BG)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1016/j.jacig.2024.100382
- Citations
- 1
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.38